Literature DB >> 26629071

Correlation of serum 25-hydroxyvitamin D level with vascular calcification in hemodialysis patients.

Fang Wang1, Shukun Wu1, Yizhe Ruan1, Li Wang1.   

Abstract

OBJECTIVE: The aim of this study was to analyze the correlation of serum 25-hydroxyvitamin D level with vascular calcification in patients treated with hemodialysis.
METHODS: As a cross-sectional study, 126 patients receiving maintenance hemodialysis (MHD) in our hospital were enrolled in this study. According to the serum 25-hydroxyvitamin D level, the patients were divided into 25-hydroxyvitamin D deficiency group (30 ηg/ml or less than 30 ηg/ml) and 25-hydroxyvitamin D normal level group (>30 ηg/ml). All of the subjects underwent lateral lumbar, pelvis and hands X-ray examination to score the degree of calcification (Kauppila score).
RESULTS: Among the 126 patients treated with MHD, there were 110 patients with 25-hydroxyvitamin D deficiency and 16 patients with normal 25-hydroxyvitamin D level. There was no significant difference found in gender, age, age of dialysis, active vitamin D treatment, blood calcium, blood phosphorus, blood parathyroid hormone (PTH) and other related indicators between the two groups. The incidence of vascular calcification in patients with 25-hydroxyvitamin D deficiency was significantly higher than that in patients with normal 25-hydroxyvitamin D level (P = 0.001). Serum 25-hydroxyvitamin D level had a negative correlation with the calcification score (r = 0.193, P = 0.193). Logistic regression showed that 25-hydroxyvitamin D was not a risk factor for vascular calcification in MHD patients. Serum 25-hydroxyvitamin D level is generally low in patients with MHD.
CONCLUSIONS: Patients with 25-hydroxyvitamin D deficiency have a higher incidence of vascular calcification with a markedly negative correlation. Thus, for the patients treated with MHD, vitamin D deficiency should be actively treated.

Entities:  

Keywords:  25-hydroxyvitamin D; Maintenance hemodialysis; calcification score; vascular calcification

Year:  2015        PMID: 26629071      PMCID: PMC4658960     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  27 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.

Authors:  J Blacher; A P Guerin; B Pannier; S J Marchais; G M London
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

3.  Oral active vitamin D is associated with improved survival in hemodialysis patients.

Authors:  Manuel Naves-Díaz; Daniel Alvarez-Hernández; Jutta Passlick-Deetjen; Adrian Guinsburg; Cristina Marelli; Diego Rodriguez-Puyol; Jorge B Cannata-Andía
Journal:  Kidney Int       Date:  2008-07-16       Impact factor: 10.612

Review 4.  Clinical epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

Review 5.  Noncalcemic actions of vitamin D receptor ligands.

Authors:  Sunil Nagpal; Songqing Na; Radhakrishnan Rathnachalam
Journal:  Endocr Rev       Date:  2005-03-29       Impact factor: 19.871

6.  Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events.

Authors:  N D Wong; J C Hsu; R C Detrano; G Diamond; H Eisenberg; J M Gardin
Journal:  Am J Cardiol       Date:  2000-09-01       Impact factor: 2.778

7.  Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients.

Authors:  Christiane Drechsler; Stefan Pilz; Barbara Obermayer-Pietsch; Marion Verduijn; Andreas Tomaschitz; Vera Krane; Katharina Espe; Friedo Dekker; Vincent Brandenburg; Winfried März; Eberhard Ritz; Christoph Wanner
Journal:  Eur Heart J       Date:  2010-08-05       Impact factor: 29.983

8.  Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease.

Authors:  Mhairi K Sigrist; Maarten W Taal; Peter Bungay; Christopher W McIntyre
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-10       Impact factor: 8.237

9.  Chronic kidney disease, hypovitaminosis D, and mortality in the United States.

Authors:  Rajnish Mehrotra; Dulcie A Kermah; Isidro B Salusky; Myles S Wolf; Ravi I Thadhani; Yi-Wen Chiu; David Martins; Sharon G Adler; Keith C Norris
Journal:  Kidney Int       Date:  2009-08-05       Impact factor: 10.612

10.  Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet.

Authors:  Wei Ling Lau; Elizabeth M Leaf; Ming Chang Hu; Marc M Takeno; Makoto Kuro-o; Orson W Moe; Cecilia M Giachelli
Journal:  Kidney Int       Date:  2012-08-29       Impact factor: 10.612

View more
  3 in total

1.  Prevalence of abdominal artery calcification in dialysis patients with end-stage renal disease: a systematic review and meta-analysis.

Authors:  Zhihui Yao; Congxia Wang; Qiaona Zhang; Shan Ma; Baosong Gui; Chaoyang Duan
Journal:  Int Urol Nephrol       Date:  2017-09-21       Impact factor: 2.370

2.  Association between vitamin D levels and mortality in hemodialysis patients: a cohort study.

Authors:  Maryanne Machado da Silva Canhos; Rogério Carvalho de Oliveira; Luis Gustavo Modelli de Andrade; Jacqueline Costa Teixeira Caramori; Pasqual Barretti; Luis Cuadrado Martin
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

3.  Validation of the Chinese version of the low physical activity questionnaire (LoPAQ) with ActiGraph accelerometer in hemodialysis patients.

Authors:  Rui Huang; Haifen Zhang; Yan Yang; Nina Fang; Qian Liu; Jun Ma; Min Wang; Ling Shi; Xingjuan Tao
Journal:  BMC Nephrol       Date:  2021-01-08       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.